Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) insider Pascal Deschatelets sold 69,107 shares of the firm's stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company's stock, valued at $60,452,799.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Apellis Pharmaceuticals Trading Up 2.4 %
APLS stock opened at $55.12 on Wednesday. The company has a market capitalization of $6.65 billion, a PE ratio of -12.30 and a beta of 0.88. Apellis Pharmaceuticals, Inc. has a one year low of $19.83 and a one year high of $94.75. The company's 50 day moving average price is $62.03 and its two-hundred day moving average price is $56.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10.
Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI
From Banyan Hill Publishing | Ad
Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.”
Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.
Click on Adam's shiny forehead for more details.
Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting the consensus estimate of ($0.73). The firm had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business's revenue was up 545.9% compared to the same quarter last year. During the same period last year, the firm posted ($1.50) earnings per share. As a group, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.36 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Apellis Pharmaceuticals by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company's stock worth $572,003,000 after buying an additional 85,701 shares during the period. Sierra Summit Advisors LLC purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth $222,000. Eventide Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth $12,558,000. FIL Ltd purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth $340,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Apellis Pharmaceuticals by 38.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company's stock worth $147,277,000 after buying an additional 677,098 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently commented on APLS shares. Wells Fargo & Company lowered shares of Apellis Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $67.00 to $54.00 in a research report on Thursday, December 14th. Raymond James lifted their target price on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a "strong-buy" rating in a research report on Thursday, January 11th. Oppenheimer lifted their target price on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an "outperform" rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. lifted their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an "overweight" rating in a research report on Wednesday, March 6th. Finally, Mizuho reiterated a "neutral" rating and set a $60.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $78.60.
Get Our Latest Analysis on APLS
Apellis Pharmaceuticals Company Profile
(
Get Free Report)
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
